The use of regorafenib in colorectal cancer

封面

如何引用文章

全文:

详细

Colorectal cancer is the third most common type of cancer in men and the second in women worldwide. The data demonstrate the increase in the annual incidence of colorectal cancer, but still the significant number of patients is detected having late-stage cancer. Regorafenib is an oral multi-kinase inhibitor that targets kinases VEGF1, VEGF2, VEGF3, PDGFR, and FGFR involved in the regulation of tumor angiogenesis, and KIT, RET, RAF-1, BRAF involved in oncogenesis. The application of regorafenib has shown statistically significant increase of progression-free survival and overall survival, thus regorafenib been approved for the treatment of metastatic colorectal cancer, associated with resistance to fluoropyrimidine, oxaliplatin or irinotecan-based therapy in combination with the VEGR inhibitor and anti-EGFR-antibodies in patients with wild type KRAS gene. The article deals with the results of major studies carried out to explore the characteristics and efficacy and safety evaluation of regorafenib. We have analyzed in the review the results of recent studies on changes in indicators of overall survival, progression-free survival, and the efficacy of regorafenib therapy, safety and objective response.

作者简介

Marina Sekacheva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: sekach_rab@mail.ru
D. Sci. (Med.) Moscow, Russia

Nikolai Bagmet

B.V. Petrovsky Russian Scientific Center of Surgery

D. Sci. (Med.) Moscow, Russia

Anastasia Guryanova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Student Moscow, Russia

Diana Rashi

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Student Moscow, Russia

参考

  1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359-86.
  2. Goel G: Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug? Cancer Manag Res 2018; 10: 425-37.
  3. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
  4. Van Cutsem E, Ciardiello F, Seitz J.F et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. ESMO 17th World Congress on Gastrointestinal Cancer, 01-04 July 2015, Barcelona, Spain. Ann Oncol 2015; 26 (Suppl. 4): Abstract LBA-05.
  5. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol 2015; 16: 619-29.
  6. Федянин М.Ю., Гладков О.А., Гордеев С.С. и др. Практические рекомендации по лекарственному лечению рака прямой кишки. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018. Т. 8; с. 346-7.
  7. Komori A, Taniguchi H, Hamauchi S et al. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer. Oncology 2017; 93 (5): 329-35.
  8. Unseld M, Filip M, Seirl S et al. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting. Neoplasma 2018; 65 (4): 599-603.
  9. Aroldi F, Bertocchi P, Prochilo T et al. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer. Still hope after the last hope? J Chemother 2017; 29: 102-5.
  10. Antonio Avallone, Maria Carmela Piccirillo et al. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). BMC Cancer 2016; 16: 69.
  11. Sanoff H.K, Goldberg R.M, Ivanova A et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer 2018; 124 (15): 3118-26.
  12. Федянин М.Ю., Гладков О.А., Гордеев С.С. и др. Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018. Т. 8; с. 305-7.
  13. Hirano K, Kawa S, Oguchi H et al. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. J Natl Cancer Inst 1987; 79: 1261-8.
  14. Van Cutsem E, Ciardiello F, Seitz J.F et al. LBA-05 results from the large, open-label Phase IIIb CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol 2015; 26 (Suppl. 4): iv118-iv118.
  15. Клинические рекомендации «Рак ободочной кишки и ректосигмоидного отдела». Ассоциация онкологов России, Российское общество клинической онкологии, 2018.
  16. Клинические рекомендации «Рак прямой кишки». Ассоциация онкологов России, Российское общество клинической онкологии, 2018.

版权所有 © Consilium Medicum, 2019

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##